The Molecular Small Animal Imaging Center core facility (MoSAIC) at KU Leuven has further expanded its preclinical imaging capabilities with the addition of a γ-CUBE to the existing state-of-the-art in vivo imaging PET PET CT platform from MOLECUBES. The addition of this preclinical SPECT imaging capability enables novel, groundbreaking research using isotopes such as Tb161, In111 and Tc99m. These isotopes will enable MoSAIC to track both small and large molecules over a longer period of time as well as open up new possibilities to study the enhancement of therapeutic efficacy of various tumour targeting carriers. In combination with the extensive expertise for the non-invasive and longitudinal assessment of preclinical disease and therapy models at MoSAIC, this will generate new insights for improved therapy outcome and understanding of disease.

MOLECUBES NV, in partnership with LabLogic Systems Inc., has recently installed a β-X-CUBE imaging platform in the lab of Prof. Paul R. Territo at the Indiana University School of Medicine for their research supporting the MODEL-AD and TREAT-AD grants provided by NIH/NIA as consortium open science grants. The goal of these grants is to evaluate and characterize new animal models for Late Onset Alzheimer’s Disease (LOAD) and use these newly acquired insights to evaluate target engagement of novel and existing pharmaceuticals. As such, this work will advance the understanding of LOAD and provide the scientific community with an extended toolbox to accelerate research in this therapeutic area.

Read full article

The Translational Research Institute (TRI) in Brisbane has recently replaced its Inveon preclinical PET/CT with a B- and X-CUBE from MOLECUBES. The addition of this bench top imaging combination complements their existing state-of-the-art in vivo imaging infrastructure. The MOLECUBES PET/CT will facilitate the translational and basic research programs at TRI, ensuring they remain at the forefront of breakthrough discoveries. The key reasons TRI chose MOLECUBES are the high-end and high-throughput PET/CT capabilities, and the user-friendliness of the system. MOLECUBES is proud to have this institute as their first customer in Australia and is looking forward to further intensive collaborations to advance translational research.